|
Dental drug scheduled for phase II trials |
Phase II clinical trials are to be launched to examine how effective a new is drug in addressing the pain of patients having their wisdom teeth removed.
Array BioPharma announced that its small molecule p38 inhibitor will be tested at two clinical trial centres in the US, with 150 patients scheduled to take part in the study. |
|
Read more...
|
|
|
Rheumatoid arthritis drug set for phase III trials |
A new drug designed to treat patients suffering from rheumatoid arthritis is to undergo phase III trials next year, it has been announced.
Rheumatoid arthritis is a fairly common condition, with the NHS estimating the 350,000 people suffer from it in the UK alone. |
|
Read more...
|
|
|
Uveal melanoma drug enters phase II trials |
Phase II clinical trials of a new injectable drug designed to treat metastatic malignant uveal melanoma have been launched in the US.
Hana Biosciences said that the goal of the trial is to examine the efficacy of Marqibo Optisome, with the firm also collecting data regarding the safety and anti-tumour activity of the drug. |
|
Read more...
|
|
|
Phase II CAP drug trials to begin |
Multi-national phase II trials of a new antibiotic for the treatment of community-acquired pneumonia (CAP) in adult patients are set to begin soon, it has been announced.
CAP is a disease which causes the lung tissue to become inflamed after exposure to germs in the course of a patient's daily life. |
|
Read more...
|
|
|
CMV disease drug gets orphan approval |
The European Medicines Agency has granted orphan drug designation to a drug designed to prevent patients with impaired cell-mediated immunity from developing cytomegalovirus (CMV) disease.
Drug maker ViroPharma said that Camvia, an oral drug currently being studied in phase III clinical trials, had won the European nod after it had been granted orphan drug designation in the US by the Food and Drug Administration. |
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 Next > End >>
|
| Results 37 - 45 of 47 |